Navigation Links
Xoft to Present at the 26th Annual JPMorgan Healthcare Conference
Date:1/3/2008

CEO to Provide Update on the Clinical and Commercial Adoption of the

Axxent(R) Electronic Brachytherapy System

FREMONT, Calif., Jan. 3 /PRNewswire/ -- Xoft, Inc., developer of the Axxent(R) Electronic Brachytherapy System, a proprietary cancer treatment platform that utilizes X-rays to deliver non-radioactive, isotope-free radiation therapy directly to cancer sites, today announced that it will present at the 26th Annual JPMorgan Healthcare Conference. Xoft president and CEO Michael Klein will present on Thursday, January 10, 2008, at 7:30am PST at The Westin St. Francis Hotel in San Francisco.

"We are excited to have the opportunity to provide an update on the adoption of this exciting new method of delivering internal radiation therapy since we went fully commercial in Q4 of 2007," said Klein. "With breast cancer, the first FDA cleared indication for the Axxent System, we are already seeing excellent clinical results at the 10 initial clinical sites and more than a dozen commercial sites that have committed since we went commercial. Combined with strong awareness among the oncology community and the recent establishment of Medicare payment for Electronic Brachytherapy in the outpatient hospital setting, we expect rapid and widespread commercial adoption, making it available to women who want to take advantage of breast conserving therapy."

Cleared by the U.S. Food & Drug Administration (FDA) for the treatment of early stage breast cancer, the Axxent System is designed to deliver therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue. Eliminating the need for heavily shielded environments, it gives radiation oncologists the flexibility to deliver therapy in a broader range of clinical settings.

Use of the Axxent Electronic Brachytherapy System also provides the opportunity to reduce the time required for radiation therapy for early stage breast cancer from seven weeks (for external radiation therapy) down to five days. As a result, tens of thousands of patients will have greater access to therapy that is delivered more easily and conveniently. This may accelerate patient choice of breast sparing lumpectomy surgery with adjuvant radiation therapy over the alternative of a full mastectomy.

The American Medical Association (AMA) Common Procedural Terminology (CPT) Editorial Panel recently approved a CPT Code for the use of electronic brachytherapy. Effective July 2007, the CPT code for electronic brachytherapy is included in the AMA CPT 2008 codebook. Additionally, the Category III CPT Code 0182T: high dose rate electronic brachytherapy, per fraction, has been assigned a New Technology Ambulatory Payment Classification (APC). The APC payment applies to the outpatient hospital and ambulatory surgical center settings and includes the high dose rate electronic brachytherapy radiation treatment and the cost of the X-ray source.

About Xoft, Inc.

Xoft is developing leading-edge new technologies for the practice of radiation oncology through Electronic Brachytherapy, which utilizes proprietary miniaturized x-ray tube technology. The Axxent(R) Electronic Brachytherapy System, Xoft's first treatment system, is currently being used in Accelerated Partial Breast Irradiation (APBI) for the treatment of early-stage breast cancer. This solution provides a therapeutic dose of intracavitary radiation directly to the region at risk without the complex handling and resource logistics necessary when performing brachytherapy using radioactive isotopes.

Axxent is a registered trademark of Xoft, Inc.


'/>"/>
SOURCE Xoft, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Danaher to Present at J.P. Morgan Healthcare Conference
2. Ikaria to Present at 26th Annual JPMorgan Healthcare Conference
3. Thoratec Presentation at JP Morgan Conference to be Webcast
4. Caliper Life Sciences to Present at JPMorgan 26th Annual Healthcare Conference
5. Medarex to Present at the 26th Annual JPMorgan Healthcare Conference
6. CryoLife to Present at OneMedPlace Finance Forum
7. Exelixis Announces January 10 Webcast of Presentation at the 26th Annual JPMorgan Healthcare Conference
8. Onyx Pharmaceuticals to Present at JPMorgan Healthcare Conference
9. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
10. Beckman Coulter to Present at the JPMorgan Healthcare Conference
11. Thermo Fisher Scientific to Present at the 26th Annual JPMorgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... ProMIS Neurosciences (“ProMIS” or the ... diseases, today announced it has issued a scientific white paper entitled “Results from ... series of commentaries from ProMIS’s scientific team offering insight into the Company’s product ...
(Date:2/22/2017)... Linda, Ca (PRWEB) , ... February 22, 2017 , ... ... innovators, engineers, and scientists from around the world, is pleased to announce the launch ... science, technology, engineering and mathematics (STEM) fields. , This merit-based scholarship is open to ...
(Date:2/22/2017)... 2017 Origin (Origin Agritech, LLC, a subsidiary of Origin ... and Arcadia (Arcadia Biosciences, Inc., NASDAQ: RKDA), ... agricultural productivity traits and nutritional products, today announced their collaboration to ... in China to the United ... ...
(Date:2/22/2017)... VIRGINIA (PRWEB) , ... February 22, 2017 , ... ... today that Dr. Daniel Spyker, PhD, MD former Acting Deputy Director in the ... CDER’s Pilot Drug Evaluation Staff has joined the company as an Expert Consultant. ...
Breaking Biology Technology:
(Date:2/13/2017)... SAN FRANCISCO , Feb. 13, 2017 /PRNewswire/ ... a centralized platform that is designed to enhance ... the latest release in the RSA Fraud & ... to enable organizations to leverage additional insights from ... anti-fraud tools to better protect their customers from ...
(Date:2/8/2017)... (NASDAQ: AWRE ), a leading supplier of biometrics ... and year ended December 31, 2016. Revenue ... to $6.9 million in the same quarter last year. Operating ... compared to $2.6 million in the fourth quarter of 2015. ... million, or $0.02 per diluted share, which compares to $1.8 ...
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
Breaking Biology News(10 mins):